Drug intelligence / Profile preview

A9Z

Development stage: Preclinical
Lead developer: ImunoTera
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

A9Z is a monoclonal antibody developed by ImunoTera, currently in the preclinical stage of development. It is designed to target and neutralize both Zika virus (ZIKV) and Dengue virus (DENV). By binding to specific viral epitopes, A9Z aims to prevent viral entry into host cells and mitigate the progression of Zika virus infection and Dengue fever. This dual-targeting approach is particularly relevant given the structural similarities and clinical overlap between these two flaviviruses.

Beyond the preview

Go deeper on A9Z.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A9Z.

Explore the full profile